Atara Biotherapeutics to Host EBV and MS Day
16 March 2022 - 7:01AM
Business Wire
Scientific Experts Join Atara Management Team
to Discuss Role of EBV in MS and Clinical Development of ATA188
Live Conference Call and Webcast on March 22 at
4:00 p.m. EDT
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell
immunotherapy, leveraging its novel allogeneic Epstein-Barr virus
(EBV) T-cell platform to develop transformative therapies for
patients with cancer and autoimmune diseases, will host an EBV and
multiple sclerosis (MS) Day on Tuesday, March 22, 2022 from 4:00 –
6:00 p.m. EDT.
Dr. Pascal Touchon, President and Chief Executive Officer along
with other members of the Atara management team, will present a
comprehensive overview of several topics including: EBV as the
cause of MS; history and development of ATA188; review of Phase 1
clinical and biomarker data; and an overview of upcoming key
catalysts.
The Atara management team will be joined by the following
renowned scientific experts, who will also share their
perspectives:
- Mark Freedman, HBSc, MSc, MD, CSPQ FANA, FAAN, FRCPC,
Professor of Medicine (Neurology), University of Ottawa and
Director of MS Research, Ottawa Hospital Research Institute,
Ottawa, Canada
- Rajiv Khanna, BSc, MSc, PhD, Director of Immunology,
QIMR Berghofer Medical Research Institute, Brisbane, Australia
- Lawrence Steinman, MD, Professor of Neurology and
Neurological Sciences, Pediatrics and Genetics, Stanford
University, Stanford, California
Analysts and investors can participate in the conference call by
dialing 877-407-8291 for domestic callers and 201-689-8345 for
international callers, using the conference ID 13727293. A live
webcast with accompanying slides can be accessed by visiting the
Investors & Media – News & Events section of atarabio.com.
An archived replay will be available on the Company's website for
60 days following the live webcast.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell
immunotherapy leveraging its novel allogeneic EBV T-cell platform
to develop transformative therapies for patients with serious
diseases including solid tumors, hematologic cancers and autoimmune
disease. With our lead program in Phase 3 clinical development and
currently under review to support registration in Europe, Atara is
the most advanced allogeneic T-cell immunotherapy company and
intends to rapidly deliver off-the-shelf treatments to patients
with high unmet medical need. Our platform leverages the unique
biology of EBV T cells and has the capability to treat a wide range
of EBV-associated diseases, or other serious diseases through
incorporation of engineered CARs (chimeric antigen receptors) or
TCRs (T-cell receptors). Atara is applying this one platform, which
does not require TCR or HLA gene editing, to create a robust
pipeline including: tab-cel in Phase 3 development for Epstein-Barr
virus-driven post-transplant lymphoproliferative disease (EBV+
PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy
targeting EBV antigens as a potential treatment for multiple
sclerosis; and multiple next-generation chimeric antigen receptor
T-cell (CAR-T) immunotherapies for both solid tumors and
hematologic malignancies. Improving patients’ lives is our mission
and we will never stop working to bring transformative therapies to
those in need. Atara is headquartered in South San Francisco and
our leading-edge research, development and manufacturing facility
is based in Thousand Oaks, California. For additional information
about the company, please visit atarabio.com and follow us on
Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220315006164/en/
Investors Eric Hyllengren 805-395-9669
ehyllengren@atarabio.com
Media Alex Chapman 805-456-4772 achapman@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Apr 2024 to May 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From May 2023 to May 2024